Research

Hormonal

Dapagliflozin (5-10 mg) significantly improves glycemic control (HbA1c reduction) in Type 2 Diabetes patients over 12 months with a favorable safety profile, despite a small risk of genital infections and rare DKA.

If you have Type 2 Diabetes, Dapagliflozin (5-10mg daily) is an effective, well-tolerated option to lower your HbA1c. It works by helping your kidneys excrete excess sugar. While it slightly increases the risk of genital itching or yeast infections, serious side effects are rare. It is often used alongside diet, exercise, and other diabetes medications.

ModerateSupportsMEDIUM confidence
Dapagliflozin was found to be a well tolerated and effective treatment option for T2DM patients in Saudi Arabia... The mean (SD) HbA1c% level significantly decreased from 8.6 (1.6) % at baseline to reach 7.2 (1.2) % after 12 months of treatment (p < 0.0001).
Abdullah M. Alguwaihes · Diabetes Therapy · 2021

Why this rating

Single-arm, non-interventional, real-world post-marketing study (PASS) without a control group; prone to bias but reflects real-world efficacy.

Source

Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study

Abdullah M. Alguwaihes · Diabetes Therapy · 2021

DOI 10.1007/s13300-021-01092-0

cohort · n=524Cited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →